Inactive Instrument

Medizone International Inc Stock OTC Bulletin Board

Equities

US5850131054

Sales 2016 237K Sales 2017 - Capitalization 16.3M
Net income 2016 -2M Net income 2017 -2M EV / Sales 2016 190 x
Net Debt 2016 1.59M Net Debt 2017 1.98M EV / Sales 2017 -
P/E ratio 2016
-15.4 x
P/E ratio 2017
-7.97 x
Employees -
Yield 2016 *
-
Yield 2017
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
Medizone International, Inc. Went Out of Business CI
Edwin G. Marshall and Jill C. Marshall cancelled the acquisition of substantially all assets of Medizone International, Inc. (OTCPK:MZEI.Q). CI
Edwin G. Marshall and Jill C. Marshall entered into a purchase and sale agreement to acquire substantially all assets of Medizone International, Inc. (OTCPK:MZEI.Q) for $0.5 million. CI
Motion for Asset Sale Approved for Medizone International, Inc. CI
Bidding Procedure Approved for Medizone International, Inc. CI
Medizone International, Inc. Bankruptcy Case Dismissed CI
Motion for Asset Sale Filed by Medizone International, Inc. CI
Final DIP Financing Approved for Medizone International, Inc. CI
Interim DIP Financing Approved for Medizone International, Inc. CI
Medizone International, Inc. Filed for Bankruptcy CI
Medizone International and Innovasource Implement & Expand Exclusive AsepticSure® Product Evaluation Agreement CI
Medizone International, Inc. Announces Resignation of Philip A. Theodore as Executive Vice President Operations and Administration, General Counsel and Corporate Secretary CI
Involuntary Petition Filed Against Medizone International, Inc. CI
Medizone International, Inc. Auditor Raises 'Going Concern' Doubt CI
Medizone International, Inc. announced that it expects to receive $10.29 million in funding from L2 Capital, LLC, Sea Otter Global Ventures LLC CI
More news
Managers TitleAgeSince
Director of Finance/CFO 54 16-09-30
President 76 01-12-31
Members of the board TitleAgeSince
Director/Board Member 65 17-05-18
President 76 01-12-31
Director/Board Member 73 14-10-07
More insiders
Medizone International, Inc. is engaged in designing, manufacturing and selling a system using ozone in the disinfection of surgical and other medical treatment facilities and in other applications. The Company's AsepticSure is an ozone-based technology, which is used for the purpose of decontaminating and disinfecting hospital surgical suites, emergency rooms, intensive care units and other enclosed spaces, such as gym locker rooms, laboratories and veterinary clinics. In the AsepticSure system, oxygen atoms are misted into the environment with a hydrogen peroxide vapor and the system's formula creates Trioxidane. The Company is developing a variant of AsepticSure for governmental use with bio-terrorism countermeasures. AsepticSure has completed safety and preliminary operational trials. During the tests, AsepticSure has demonstrated a turnaround time of approximately 90 minutes for disinfection and reoccupation of the hospital rooms.
Sector
-
More about the company